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Virtual screeningThe interaction between HIV-1 integrase and LEDGF/P75 has been validated as a target for anti-HIV
drug development. Based on the crystal structure of integrase in complex with LEDGF/P75, a library
containing 80 thousand natural compounds was ﬁltered with virtual screening. 11 hits were
selected for cell based assays. One compound, 3-(1,3-benzothiazol-2-yl)-8-{[bis(2-hydroxy-
ethyl)amino]methyl}-7-hydroxy-2H-chromen-2-one (D719) inhibited integrase nuclear transloca-
tion in cell imaging. The binding mode of D719 was analyzed with molecular simulation. The
anti-HIV activity of D719 was assayed by measuring the p24 antigen production in acute infection.
The structure characteristics of D719 may provide valuable information for integrase inhibitor
design.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Human immunodeﬁciency virus (HIV) is the virus that causes
the fatal acquired immunodeﬁciency syndrome (AIDS) [1]. The
HIV life cycle is usually divided into six steps: attachment and
fusion, reverse transcription, integration of viral DNA into host
genome, transcription, assembly and budding [2,3]. Integrase, also
called p31, is the enzyme responsible for integration. Integrase is
consisted of three domains: N-termianl domain (NTD, residues
1–49), catalytic core domain (CCD, residues 50–212) and C-termi-
nal domain (CTD, residues 213–288) [4]. Integration of viral provi-
rus into the human genome is a critical event for HIV infection,
through which the permanent infection is constructed and this
process is irreversible [5]. The integration process includes two
steps called 30-terminal processing and strand transfer. The 30-ter-
minal processing step is completed in cytoplasm by speciﬁc mod-
iﬁcation of the viral DNA. Then the viral DNA is transported into
cell nucleus for strand transfer and the following gap repair [5].
In the similar situation with reverse transcriptase (RT) and prote-
ase (PR), integrase (IN) was regarded as an effective target for
anti-AIDS research in the early 1990’s. Five monoclonal antibodies(mAbs) against N-terminal domain of 58 amino acids, 2 mAbs
against 29 amino acids at the C terminus and 2 mAbs against the
D,D (35)E domain in CCD of IN were developed for anti-HIV trials
[6]. The ﬁrst reported HIV-1 integrase inhibitor was AR-177, an oli-
gonucleotide, inhibiting HIV infection by stoping the provirus from
being incorporated into host genome [7]. Strand transfer step has
been targeted for anti-HIV drug discovery in the last decades. Many
trials have been performed to ﬁnd drugs to stop virus infection at
strand transfer step. The ﬁrst FDA approved integrase inhibitor, ral-
tegravir (RAL), ﬁnally appeared in 2007 after a long time of devel-
opment [8]. RAL is an important addition to the highly activite
antiretroviral therapy (HAART) for AIDS treatment. Another two
integrase inhibitors, elvitegravir (EVG) and dolutegravir (DTG)
have been approved in 2012 and 2013 for treatment of HIV
infected patients [9–11]. All the three inhibitors are integrase
strand transfer inhibitors. A ﬂuorometric assay was developed for
targeting 30-processing step although no integrase inhibitor against
this target have been approved [12]. The protein–protein interac-
tions (PPIs) between HIV integrase and host factors have been
regarded as promising targets for anti-HIV research. There are sev-
eral human proteins have been reported to interact with integrase,
among which lens epithelium-derived growth factor/transcription
co-activator p75 (LEDGF/p75) calls much attention [13,14]. Resi-
dues 347–429 of LEDGF/p75 is called integrase binding domain
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ture of CCD-IBD dimer complex was disclosed in 2005 although the
full length integrase structure is not available [15]. Based on the
disclosed crystal structure, one benzoic acid derivative (D77 from
the SPECS bank), was discovered by virtual screening and blocked
integrase nuclear translocation by interrupting IN-LEDGF/p75
interaction. The structure of D77 is shown in Fig. 2 [16]. In this
study, we discovered one natural compound (D719, 3-(1,3-ben-
zothiazol-2-yl)-8-{[bis(2-hydroxyethyl)amino]methyl}-7-hydroxy
-2H-chromen-2-one) from ZINC database (www.zinc.com) by
structure based virtual screening and bioassays which inhibited
integrase nuclear translocation and showed signiﬁcant inhibition
on virus p24 antigen production.
2. Materials and methods
2.1. Protein structure preparation
The IN CCD-LEDGF/p75 IBD dimer complex crystal structure
was downloaded from Protein Data Bank (PDB ID: 2B4J). The IBD
part was removed from the structure. Water molecules were
deleted. Then the CCD dimer was prepared with AutoDock Tools
1.5.4 for docking preparation for AutoDock.
2.2. Ligand preparation
Totally 80 thousand natural compound structures were down-
loaded from ZINC database. The structures were converted into
pdbqt ﬁles by Raccoon 1.0.
2.3. Virtual screening
The gridbox was optimized according to the IBD binding site.
The center of the gridbox was set as: center_x = 14.685, cen-
ter_y = 4.189, center_z = 7.387. The grid map with 40  40  40
points and a spacing of 0.375 Å was used for screening. The pro-
tein–ligand interactions were dealed with Lamarckian genetic
algorithm (LGA). Ligands were docked into the binding pocket of
CCD dimer with the AutoDock Vina program, and were ranked
according to the scores that were calculated with the energy scor-
ing function in the AutoDock software. Other screening parameters
were set as default. The interaction was analyzed according to the
pose with the lowest binding energy by PyMol (www.pymol.org). A
library containing 80 thousand natural compounds from ZINC
database was screened. The top 11 hits were purchased from
Chembridge (http://www.chembridge.com, D719, D217, D385)
and Molport (http://www.molport.com, D746, D574, D103, D249,
D786, D683, D571, D261).Fig. 1. Schematic representation of virtual screening strategy. The integrase CCD
dimer was isolated from the complex of protein crystal structure (PDB ID: 2B4J) and
prepared for virtual screening. Ligands from the ZINC database were transformed
into pdbqt ﬁles. The virtual screening was performed by AutoDock Vina. The
screening results were analyzed visually. Top hits were selected for in vitro assays.2.4. Plasmids
pTRE2hyg expression vector (Clontech) containing HIV-1
integrase gene fused with enhanced green ﬂuorescent protein
(EGFP) at the N-terminal and pcDNA6/V5-HisA (Invitrogen) vector
containing HIV-1 integrase were kept in the lab in The Chinese
University of Hong Kong.
2.5. Cell culture and cell based screening
HeLa Tet-Off Advanced Cells (Clontech) were cultured according
to the instruction from Clontech. The culture medium was Dul-
becco’s modiﬁed Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1% of streptomycin–penicillin (Invit-
rogen), 100 lg/ml G418 at 37 C in a 5% CO2 incubator. The cell
based screening was performed as described before [17]. One day
before transfection, 5  104 cells were seeded onto a black/clear
96-well plate (BD) in DMEM containing 10% FBS. Recombinant
pTRE2hyg vector was transfected into cells using Lipofectamine
2000 reagent (Invitrogen) in accordance with the manufacturer’s
instruction. The medium was changed 5 h after transfection with
medium containing compound solution. Compound was added at
ﬁnal concentrations of 1 lM, 5 lM and 10 lM separately. DMSO
was used as control. The second day, cells were ﬁxed with 4% para-
formaldehyde for 15 min at room temperature (RT). Leica SP5 con-
focal microscopy was used for cell imaging.
2.6. Immunoﬂuorescence assay
Transfection and solution of compounds were as described
above. The immunoﬂuorescence assay was performed as described
before [17]. Details were as follows. The second day after transfec-
tion, cells were ﬁxed with 4% paraformaldehyde. The cells were
rinsed in PBS and made permeable in 0.5% Triton X-100. After
washed with PBS, the cells were incubated in 3% bovine serum
albumin (BSA) for 1 h. Cells were washed in PBS, and incubated
in anti-integrase-1 antibody (Santa Cruz Biotechnology) diluted
with PBS containing 1% BSA at 37 C in a humid chamber for 1 h.
Then cells were washed for 30 min in three changes of PBS and
then incubated in FITC-conjugated antibody (Santa Cruz Biotech-
nology) diluted with PBS containing 1% BSA at 37 C in a humid
chamber for 1 h. Then cells were washed with PBS. Cells were
stained with propidium iodide (PI, 0.3 lg/ml) for 20 min at RT.
Leica SP5 confocal microscopy was used for cell imaging.
2.7. HIV-1 p24 production inhibition in acute infection
HIV-1IIIB (The laboratory-adapted IIIB HIV-1 strain) was used in
acute infection assay. C8166 cell line and HIV-1IIIB were supplied
by British Medical Research Council, AIDS Reagent Project. AS
one of the major structural proteins of HIV, p24 is an indicator of
progression of virus infection [18,19]. The p24 antigen production
was measured according to the previously reported method [20].
C8166 cells were infected with HIV-1IIIB (MOI = 0.15) at 37 C in a
5% CO2 humidiﬁed incubator for 2 h. Culture medium was
removed. Cells were washed for three times with PBS. Then the
cells (4  104 cells) were seeded with compounds at 0.5–20 lM
and incubated at 37 C in a 5% CO2 humidiﬁed incubator for 3 days.
The supernatants were collected and mixed with 5% Triton X-100.
HIV-1 p24 was assayed by ELISA. Anti-Fc antibody was embedded
1 lg/well at 4 C for overnight. Wells were blocked for 2 h at 37 C
with 5% defatted milk powder. 100 ll mouse anti-p24 antibody
was added to each well and incubated for 1 h at 37 C. 100 ll cell
culture supernatant was added to each well and incubated for
2 h at 37 C. 100 ll rabbit anti-p24 antibody was added to each
well and incubated for 1 h at 37 C. 100 ll HRP-conjugated goat
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Fig. 2. Structures of the 11 hits and D77. Virtual screening was performed for compounds that bind with high afﬁnity to integrase CCD dimers, and the structures of the 11
hits are presented here. A reported compound, D77, was used as control for analysis of the interaction between compound and integrase. The structure of D77 is also
presented here.
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Fig. 2 (continued)
Table 1
Physical representations of the compounds.
Compound xlogP H-bond donors H-bond acceptors Molecular weight (g/mol) Rotatable bonds
D719 2.73 4 7 413.475 7
D217 4.71 0 7 453.45 6
D385 1.24 6 8 402.41 6
D746 6.30 1 5 457.533 2
D574 6.64 1 5 509.915 3
D103 6.32 1 5 457.533 2
D249 4.52 0 4 438.502 2
D261 4.87 1 6 460.537 2
D683 6.37 1 6 521.613 3
D571 5.79 1 5 441.918 2
D786 6.32 1 5 457.533 2
3464 W.-G. Gu et al. / FEBS Letters 588 (2014) 3461–3468anti-rabbit IgG was added to each well and incubated for 1 h at
37 C. OPD was used as substrate. 2 M sulfuric acid was added
for 10 min. The OD was read with Elx800ELISA at 490 nm (refer-
ence wavelength was 630 nm).Table 2
The virtual binding afﬁnity of the 11 hits and D77.
Compound Afﬁnity (kcal/mol)
D719 9.2
D217 9.1
D385 8.9
D746 9.8
D574 9.2
D103 9.2
D249 9.0
D261 8.9
D683 9.3
D571 8.9
D786 9.1
D77 9.33. Results
3.1. Structure based virtual screening
The structure based virtual screening was performed with Auto-
Dock Vina. A library containing 80 thousand natural compounds
from ZINC database was ﬁltered for integrase inhibitor discovery.
The prepared ligands were docked into the binding pocket of IN
CCD as described in materials and methods. Then the poses were
analyzed with PyMol. Top 11 hits with highest binding activity
were purchased for experiments. The workﬂow of the virtual
screening was shown in Fig. 1. The 11 compounds for cell basedassays are listed in Table 1. Structures of the 11 compounds are
shown in Fig. 2. The virtual binding afﬁnity of the 11 hits and
D77 is shown in Table 2.
BA
Fig. 3. D719 inhibited EGFP-IN nuclear translocation. EGFP-IN expression vector was transfected into HeLa Tet-Off Advanced Cells. Transfection result was analyzed with
Leica SP5 confocal microscopy. Confocal imaging showed that D719 blocked integrase nuclear translocation at 1 lM (A). Without compound, EGFP-IN was mainly localized in
nucleus (B). Scale bar is 50 lm.
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screening
To identify the compounds that interfere with IN nuclear trans-
location, EGFP-IN expression vector pTRE2hyg was transfected into
HeLa Tet-Off Advanced Cells to monitor the translocation process.
IN-EGFP was mainly localized in cellular nucleus (Fig. 3B). In the
presence of the compound D719, the EGFP tagged IN accumulated
in the peripheral area of the nucleus (Fig. 3A). The minimal effec-
tive concentration is 1 lM. The other 10 compounds showed no
inﬂuence on IN nuclear translocation.
3.3. D719 inhibited IN nuclear translocation in immunoﬂuorescence
assay
To conﬁrm that D719 inhibited integrase nuclear translocation
and had no interaction with EGFP, IN expression vector pcDNA6/
V5-HisA (Invitrogen) was transfected into HeLa cells for immuno-
ﬂuorescence assay. FITC-conjugated anti-HIV-1 IN polyclonal anti-
body (Santa Cruz Biotechnology) was used to label IN in
immunoﬂuorescence assay. The nucleus was stained by PI. Cell
imaging showed that integrase nuclear translocation was inhibitedby D719 at 10 lM (Fig. 4A1–A3). Without treatment of D719 (With
DMSO), integrase was mainly localized in the nucleus (Fig. 4B1–
B3).
3.4. Interaction between D719 and IN CCD
The binding mode of D719 to IN was analyzed with PyMol and
Ligplot (http://www.ebi.ac.uk/thornton-srv/software/LIGPLOT/).
The Docking mode of D719 with integrase is showed as Fig. 5.
D719 was docked into the hydrophobic pocket formed by sur-
rounding residues of IN CCD (Fig. 5A and B). D719 formed H-bonds
with Thr125B with a distance of 3.08 Å and Glu170A with a dis-
tance of 3.09 Å (Fig. 5C). O24 of D719 formed two H-bonds with
OG1 of Thr174A with a distance of 3.05 Å and N of His171A with
a distance of 2.94 Å. O27 of D719 formed two H-bonds with NE2
and OE1 of Gln95B with distance of 3.24 Å and 2.92 Å respectively
(Fig. 5C). Besides, D719 formed hydrophobic contacts with Gln168
A, Ala169A, Ala128B, Trp131B, Ala129B respectively (Fig. 5C). As
described previously, D77 (O20) forms H-bond with Thr125B
(OG1) with a distance of 2.90 Å. D77 (O35) forms two H-bonds
with Arg166A (NH1 and C) with distance of 2.93 Å and 3.10 Å,
respectively. D77 forms hydrophobic contacts with Leu102B,
Fig. 4. D719 inhibited IN nuclear translocation. Immunoﬂuorescence assay showed that D719 inhibited IN nuclear translocation at 10 lM (A1–A3). IN was localized into the
nucleus when D719 was substituted with DMSO (B1–B3). The nuclei were stained with PI and shown in red.
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[16,17]. The comparison of binding modes of D719 and D77 to IN
CCD is shown in Fig. 5D.
3.5. D719 reduced HIV-1 p24 production in acute infection
D719 showed HIV-1 IN nuclear translocation inhibition in cell
based imaging (Figs. 3 and 4). Interaction analysis showed that
D719 binds to the hydrophobic pocket with H-bonds and hydro-
phobic contacts mainly. The inﬂuence of D719 on HIV-1 replication
in vitro was further assayed by quantiﬁcation of p24 expression
using capture ELISA as described previously. D719 dramatically
reduced p24 production in HIV-1IIIB acute infected human T cells
with EC50 value of 4.33 lM (Fig. 6).
4. Discussion
PPI has been regarded as important target for anti-HIV drug
development. As the ﬁrst discovered host factor that interacts with
IN, LEDGF/p75 called much attention.
Circular peptides were identiﬁed to disrupt the interaction
between IN and LEDGF/p75, leading to the synthesis of peptidom-
imetics as anti-HIV agent targeting LEDGF/p75 [21,22]. More stud-
ies are focusing on developing of small molecule integrase
inhibitors. Following the report of the ﬁrst inhibitor (D77) target-
ing IN-LEDGF/p75, the second inhibitor, C3003, was discovered
with pharmacophore-based research. C3003 showed an IC50 value
of 35 lM when tested by the AlphaScreen assay [23]. A series of
derivatives were synthesized based on the structure of C3003.
The best one, compound CHIBA 3053, showed an IC50 value of
3.5 lM as tested with the AlphaScreen method [24]. In this study,
11 compounds with high afﬁnity to IN (Fig. 2), were discovery by
structure based virtual screening from a library containing 80
thousand natural compounds from ZINC database. In cell based
screening assay, one compound, D719 inhibited EGFP tagged IN
nuclear translocation from 1 lM to 10 lM. The cell imaging resultat 1 lM was shown in Fig. 3. To conﬁrm that D719 interacts with
IN and has no inﬂuence on EGFP cellular distribution, immunoﬂu-
orescence assay was performed. D719 inhibited native IN nuclear
translocation at the minimal concentration of 10 lM (Fig. 4). The
binding mode of D719 to IN was analyzed with PyMol and Ligplot.
H-bonds and hydrophobic contacts play key role in the interaction
between D719 and IN. D719 formed H-bonds with Thr125B with a
distance of 3.08 Å and Glu170A with a distance of 3.09 Å (Fig. 5C).
O24 of D719 formed two H-bonds with OG1 of Thr174A with a dis-
tance of 3.05 Å and N of His171A with a distance of 2.94 Å. O27 of
D719 formed two H-bonds with NE2 and OE1 of Gln95B with dis-
tance of 3.24 Å and 2.92 Å, respectively (Fig. 5C). Besides, D719
formed hydrophobic contacts with Gln168 A, Ala169A, Ala128B,
Trp131B, Ala129B respectively (Fig. 5C).
The primary residues of integrase that interact with LEDGF/p75
are residues 168–171 in chain A and residues which form the
alpha-helices 1 and 3 of Chain B [15]. Some primary residues are
involved in the IN-D719 interaction in molecular docking analysis
(Fig. 5). The binding of D719 to integrase may disrupt the IN-
LEDGF/p75 interaction. Since D719 is discovered through virtual
screening targeting integrase, it is difﬁcult to analyze whether
D719 interact with LEDGF/p75 by molecular docking even by
experiments. As described previously, D77 (O20) forms H-bond
with Thr125B (OG1) with a distance of 2.90 Å. D77 (O35) forms
two H-bonds with Arg166A (NH1 and C)with distance of 2.93 Å
and 3.10 Å, respectively. D77 forms hydrophobic contacts with
Leu102B, Ala129B, Asp167A Glu170A, and Met178A of IN CCD
respectively [16,17]. A comparison of the binding modes between
D719 and D77 to IN was conducted. The details were summarized
in Fig. 5D. As we can see, D719 and D77 shared seven residues
(Gln168A, Glu170A, Thr174A, Gln95B, Thr125B, Ala128B and
Ala129B) in interactions with integrase. These residues are the
key factors to form the ligand binding pocket. These residues
may play important role in drug design targeting integrase. To fur-
ther evaluate the inﬂuence of D719 on virus replication, p24 pro-
duction was measured in acute infection of HIV to human T cells.
Fig. 5. Interaction between D719 and IN CCD. (A) D719 was shown as sticks. IN CCD was shown as surface. D719 was docked into the hydrophobic pocket of IN CCD. (B) D719
was shown as sticks. The secondary structure of IN CCD was shown as cartoon. The H-bond was shown in red, labeled with distance. D719 was docked into the hydrophobic
pocket formed by surrounding residues of Chain A and Chain B. (C) O24 of D719 formed two H-bonds with OG1 of Thr174A with a distance of 3.05 Å and N of His171A with a
distance of 2.94 Å. O27 of D719 formed two H-bonds with NE2 and OE1 of Gln95B with distance of 3.24 Å and 2.92 Å, respectively. Besides, D719 formed hydrophobic
contacts with Gln168A, Ala128 B, Trp131B, Ala129B respectively. (D) Comparison of binding modes of D719 and D77 to IN CCD. The interaction between D719 and IN CCD
was as described in A–C. The interaction between D77 and IN CCD was as described previously [16,17].
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of 4.33 lM (Fig. 6). The anti-HIV activity of D719 was conﬁrmed by
this result. In this study, one compound (D719) with anti-HIV
activity was discovered through virtual screening that based onthe crystal structure of CCD dimer of HIV-1 integrase. D719 was
docked into the pocket in integrase dimer. The interaction between
D719 and CCD dimer was analyzed by molecular docking. The
binding of D719 may also change the three dimensional structure
Fig. 6. D719 reduced HIV-1 p24 production in acute infection. Compounds were
added to cell culture with HIV-1 infection at 0.5–20 lM. Results showed that D719
dramatically reduced P24 production in HIV-1IIIB acute infected C8166 cells with
EC50 value of 4.33 lM. AZT was used as control. EC50 of AZT was 1.47 ng/ml. Data
are expressed as means ± S.D.
3468 W.-G. Gu et al. / FEBS Letters 588 (2014) 3461–3468of integrase and thus disrupt the interaction between integrase
and LEDGF/p75. Without the assistance of LEDFG/p75, integrase
failed to translocate into the nucleus (Figs. 3 and 4). The discovery
of D719 may provide valuable information for new integrase inhib-
itor development.
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